ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Completed · Phase 1/Phase 2

Conditions studied: Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome, Mantle Cell Lymphoma (MCL), Indolent Non Hodgkin Lymphoma, Waldenström Macroglobulinemia, Multiple Myeloma, Hodgkin Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphomas, Mediastinal Large B Cell Lymphoma, Hairy Cell Leukemia

In brief

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Key facts

Study ID: NCT02362035
Run by: Acerta Pharma BV
People needed: 161
Starts: 2015-02-20
Expected to finish: 2025-10-27
Last updated by the study team: 2026-05-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Research Site — Boston, Massachusetts, United States
Research Site — Rochester, Minnesota, United States
Research Site — Omaha, Nebraska, United States
Research Site — Columbus, Ohio, United States
Research Site — Greenville, South Carolina, United States
Research Site — Nashville, Tennessee, United States
Research Site — Dallas, Texas, United States
Research Site — Houston, Texas, United States
Research Site — San Antonio, Texas, United States
Research Site — Tyler, Texas, United States
Research Site — Fairfax, Virginia, United States
Research Site — Roanoke, Virginia, United States
Research Site — Vancouver, Washington, United States
Research Site — Yakima, Washington, United States
Research Site — Niles, Illinois, United States
Research Site — Tucson, Arizona, United States
Research Site — Los Angeles, California, United States
Research Site — Denver, Colorado, United States
Research Site — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.